Departments of *Pathology **Urology ††Carol and James Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital ‡‡Division of Translational Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston ∥Department of Pathology, University of Massachusetts Medical School, Worcester, MA †Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou §Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, PR China ‡Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN #Department of Medicine, Division of Genomic Medicine, Institute for Human Genetics, University of California, San Francisco, CA ¶Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland.
Am J Surg Pathol. 2014 Jul;38(7):895-909. doi: 10.1097/PAS.0000000000000237.
Renal cell carcinoma (RCC) occurs in 2% to 4% of patients with tuberous sclerosis complex (TSC). Previous reports have noted a variety of histologic appearances in these cancers, but the full spectrum of morphologic and molecular features has not been fully elucidated. We encountered 46 renal epithelial neoplasms from 19 TSC patients and analyzed their clinical, pathologic, and molecular features, enabling separation of these 46 tumors into 3 groups. The largest subset of tumors (n=24) had a distinct morphologic, immunologic, and molecular profile, including prominent papillary architecture and uniformly deficient succinate dehydrogenase subunit B (SDHB) expression prompting the novel term "TSC-associated papillary RCC (PRCC)." The second group (n=15) were morphologically similar to a hybrid oncocytic/chromophobe tumor (HOCT), whereas the last 7 renal epithelial neoplasms of group 3 remained unclassifiable. The TSC-associated PRCCs had prominent papillary architecture lined by clear cells with delicate eosinophilic cytoplasmic thread-like strands that occasionally appeared more prominent and aggregated to form eosinophilic globules. All 24 (100%) of these tumors were International Society of Urological Pathology (ISUP) nucleolar grade 2 or 3 with mostly basally located nuclei. Tumor cells from 17 of 24 TSC-associated PRCCs showed strong, diffuse labeling for carbonic anhydrase IX (100%), CK7 (94%), vimentin (88%), and CD10 (83%) and were uniformly negative for SDHB, TFE3, and AMACR. Gains of chromosomes 7 and 17 were found in 2 tumors, whereas chromosome 3p deletion and TFE3 translocations were not detected. In this study, we reported a sizable cohort of renal tumors seen in TSC and were able to identify them as different morphotypes, which may help to expand the morphologic spectrum of TSC-associated RCC.
肾细胞癌 (RCC) 在结节性硬化症复合征 (TSC) 患者中发生的比例为 2%至 4%。先前的报告指出,这些癌症具有多种组织学表现,但形态学和分子特征的全貌尚未完全阐明。我们从 19 名 TSC 患者中遇到了 46 例肾上皮性肿瘤,并分析了它们的临床、病理和分子特征,使这些 46 个肿瘤分为 3 组。最大的肿瘤亚组(n=24)具有独特的形态、免疫和分子特征,包括明显的乳头状结构和均匀缺乏琥珀酸脱氢酶亚单位 B(SDHB)表达,促使提出了“TSC 相关的乳头状 RCC(PRCC)”的新术语。第二组(n=15)在形态上类似于杂交嗜酸细胞/嫌色细胞瘤(HOCT),而第 3 组的最后 7 个肾上皮性肿瘤仍无法分类。TSC 相关的 PRCC 具有明显的乳头状结构,由透明细胞排列,具有精致的嗜酸性细胞质线状结构,偶尔更明显并聚集形成嗜酸性小球。这些肿瘤的所有 24 例(100%)均为国际泌尿病理学会(ISUP)核仁等级 2 或 3,核大多位于基底部。来自 24 例 TSC 相关 PRCC 中的 17 例的肿瘤细胞表现出强烈、弥漫的碳酸酐酶 IX(100%)、CK7(94%)、波形蛋白(88%)和 CD10(83%)的阳性表达,并且均匀为 SDHB、TFE3 和 AMACR 阴性。在 2 例肿瘤中发现了染色体 7 和 17 的增益,而未检测到染色体 3p 缺失和 TFE3 易位。在这项研究中,我们报告了 TSC 中所见的大量肾肿瘤,并能够将它们鉴定为不同的形态类型,这可能有助于扩大 TSC 相关 RCC 的形态谱。